REVIEW

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data

J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Inês, E J P de Koning, F Buttgereit, M Cutolo, H Capell, R Rau, J W J Bijlsma

Ann Rheum Dis 2006;**65**:285–293. doi: 10.1136/ard.2005.038638

Adverse effects of glucocorticoids have been abundantly reported. Published reports on low dose glucocorticoid treatment show that few of the commonly held beliefs about their incidence, prevalence, and impact are supported by clear scientific evidence. Safety data from recent randomised controlled clinical trials of low dose glucocorticoid treatment in RA suggest that adverse effects associated with this drug are modest, and often not statistically different from those of placebo.

The introduction of glucocorticoids (GC) in the 1950s was a revolution in the treatment of a large variety of inflammatory diseases. Enthusiasm generated by the dramatic results led to the use of high doses, which disclosed a spectrum of toxicity that shook the foundations of this treatment. Despite this, GC still have a pivotal role in the management of diverse rheumatic conditions. The proportion of patients treated with GC by practising physicians every day is clearly in excess of the usually conservative recommendations in textbooks and review papers. Recent studies demonstrating the disease modifying potential of GC in lower dosages in rheumatoid arthritis (RA) have renewed the debate on the risk/benefit ratios of this treatment. Arguments against GC use are dominated by fear of a toxicity that is well engraved in international medical culture but which is strongly influenced by observations derived from the use of high doses of GC. Whether this fear is justified for lower dose treatment, specifically for patients with RA, has not been completely answered.

To examine this problem, a working party was organised, comprising experts with a special interest in this area, including rheumatologists and one endocrinologist from Europe and America, with representation of most groups that have conducted randomised clinical trials on the use of GC in RA. The panel agreed to perform two major tasks and the results of these are presented in this paper:

- *A literature review of the adverse effects of long term low dose GC, especially in rheumatic diseases.* The group compiled an extensive and comprehensive list of all putative adverse effects attributed to GC by a primary search of textbooks and review papers. This list was split into categories similar to those in this text. As a first step, for each category a thorough search was performed, using the adverse effects as keywords and the reference lists of the original papers. This literature was reviewed and described; the texts produced were circulated numerous times among all members of the group for critical appraisal of completeness and balance. Given that the vast majority of available data on GC is observational and retrospective and refers to diverse diseases, doses, and regimens, appreciation of the level of evidence was frequently difficult and subjective. This was resolved by reviewing the underlying data and discussion, until consensus was achieved.
- *An analysis of toxicity data from the randomised controlled trials of GC in RA.* As the working party comprised of representatives of all groups who had conducted 2 year trials on the use of GC in RA, very detailed information on adverse effects from these trials was available for discussion. Differences in methodology precluded a systemic meta-analysis of the adverse effects observed. Here, results from each trial, where available, are summed. The data incorporated in this review come from the following trials: the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study, here further designated as the ACR study,[1 2] the German study, here further designated as the LDPT (low dose prednisolone therapy) study,[3] the Utrecht study,[4] and WOSERACT[5] (table 1). Although the proposed definition of ''low dose'' is 7.5 mg prednisolone equivalent or less, to enhance readability these four trials as a group are in this paper described as ''the four extensively reviewed trials on low dose GC in RA''. More details on these trials are available through hyperlinks to the electronic version of this article on the website of the *Annals* (hyperlink 1, http://www.annrheumdis.com/supplemental). Previously unpublished detailed monitoring results from the ''combination treatment in early rheumatoid arthritis'' (COBRA) trial are included in the web version of this paper (hyperlink 2, http://www.annrheumdis.com/supplemental).

Supplementary information is available at http://www.annrheumdis.com/supplemental

See end of article for authors' affiliations

Correspondence to: Professor J A P Da Silva, Reumatologia. Hospitais da Universidade, 3000-075 Coimbra, Portugal; jdasilva@ci.uc.pt

Accepted 25 July 2005
Published Online First 17 August 2005

Abbreviations: BMD, bone mineral density; COBRA, combination treatment in early rheumatoid arthritis (trial); GC, glucocorticoid(s); GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus

Table 1 Characteristics of the four extensively reviewed rheumatoid arthritis trials using ⩽10 mg prednisone daily

Study	ARC study	LDPT study	Utrecht study	WOSERACT
Year of first publication	1995	2000	2002	2004
Reference	1, 2	3	4	5
RA duration at entry (years)	<2	<2	<1	Median 1
Number of patients, prednisolone group	61	34	40	84
Prednisolone dose/day (mg)	7.5	5	10	7
Duration of trial (years)	2	2	2	2
Associated DMARDs	Various	IM gold or MTX	Sulfasalazine rescue	Sulfasalazine

DMARDs, disease modifying antirheumatic drugs; IM, intramuscular; MTX, methotrexate.

This paper is the result of these efforts. It gives a critical and pragmatic overview of scientific evidence on the adverse effects of chronic GC treatment in lower dosages (⩽10 mg/day prednisolone equivalent) in RA in daily clinical practice.

MUSCULOSKELETAL ADVERSE EFFECTS

Osteoporosis

Osteoporosis is a well established side effect of chronic GC use. The incidence of osteoporosis is time and dose dependent, but there is no consensus about a ''safe'' dose. Although some studies suggest that doses of 7.5 mg of prednisone a day or less are relatively safe, a longitudinal study observed an average loss of 9.5% from spinal trabecular bone over 20 weeks in patients exposed to 7.5 mg of prednisolone a day.[6–8] Studies focusing on low dose treatment are relatively scarce, however. Further, it is important to recognise that in non-randomised studies, factors such as age, underlying disease, disease severity, co-medication, and duration of treatment can lead to confounding by indication for GC, and may thus preclude definite conclusions. Alternate day GC regimens have not been shown to reduce bone loss.[9 10]

In 1997, an exhaustive literature search for all prospective studies found only 18 studies and 329 patients in whom bone mass was studied prospectively while receiving GC treatment for any disease.[11] An update of this review now includes almost 1200 patients.[12] At a mean dose of almost 9 mg prednisone equivalent a day, the best estimate of bone loss overall in spine and hip (without bisphosphonate treatment) is 1.5% a year. Important positive predictive factors include starting dose and chronic usage; and in the spine, dose and lack of vitamin D supplementation.

> ''Chronic use of glucocorticoids doubles the already increased risk of osteoporosis in RA''

The consequences of this bone mass loss upon fracture rate proved to be quite significant. Although the underlying disease itself, such as RA, may be associated with an increased incidence of osteoporosis or falls, the chronic use of GC further amplifies this increased risk by a factor of 2.[13 14] In a recent multicentre cross sectional study, 205 patients with RA who were receiving daily GC orally were compared with 205 matched patients who did not receive GC. Vertebral deformities were found in 25% of patients receiving GC compared with 13% of controls. The occurrence of vertebral deformities was dose dependent.[7]

In a recent retrospective cohort study using the General Practice Research Database of the UK it was shown that the rate of clinical vertebral fractures increased by 55% for a dose of prednisolone of less than 2.5 mg/day and by over 400% if the dose exceeded 7.5 mg/day.[15] Inflammatory disease activity has been shown to be an independent risk factor for osteoporosis, at least in RA. Disease activity leads to reduced physical activity and increased levels of inflammatory cytokines, such as tumour necrosis factor α, which stimulate differentiation of osteoclasts both directly and indirectly via RANK ligand (osteoclast differentiation factor) and thus lead to bone loss. Possibly, therefore, GC in RA, leading to decreased disease activity, may cause less bone loss than they would have in the absence of inflammatory disease. Studies disagree as to whether a cumulative dose is,[8 16] or is not[15 17] associated with a degree of bone loss. A recent study showed that the greatest increase in the risk of vertebral fractures induced by GC was seen in older postmenopausal women, age being a risk factor independent of bone mineral density (BMD).[18] On the other hand, it is quite likely that, as some studies suggested, fractures occur at higher BMD levels in patients treated with GC than in patients not treated with GC.[19]

Data from the four extensively reviewed trials on low dose GC in RA showed that BMD loss over 2 years of low dose prednisone is not significantly different from that with placebo (hyperlink 1, http://www.annrheumdis.com/supplemental). The higher doses of prednisone used in the COBRA study were associated with a higher BMD loss,[20] but this difference did not reach statistical significance either (hyperlink 2, http://www.annrheumdis.com/supplemental). Fracture incidences were similar in both groups in the LTDP study.[3] However, the Utrecht group found twice the incidence of radiological vertebral fractures in the prednisone group, but this did not reach statistical significance.[4]

Osteoporosis is probably the most common adverse effect of chronic low dose GC but fortunately is preventable. Strategies for the prevention and treatment of GC-induced osteoporosis are well established and have been the object of recent extensive reviews,[19 21 22] and authoritative guidelines.[23–25]

Osteonecrosis

Osteonecrosis (avascular necrosis of bone) has been, for a long time, considered an important consequence of high dose GC use. In a Japanese study of osteonecrosis of the femoral head, 35% of all cases were related to GC treatment.[26] However, it is sometimes difficult to know whether the treatment or the underlying disease is the cause, because some conditions, such as systemic lupus erythematosus (SLE), are associated with an increased risk of osteonecrosis,[27] especially in young patients with several organs affected. This is one of the reasons why some authors question the evidence that GC are actually responsible for osteonecrosis.[28] Although the occurrence of GC related osteonecrosis seems to be dose dependent, this might be confounded by the fact that higher doses are related to more severe underlying disease and increased risk of osteonecrosis. One study reported osteonecrosis in 2.4% of patients receiving GC replacement treatment,[29] but data on low dose GC treatment are scarce and mostly anecdotal. At least in SLE, a higher average dose may be a more important

predictor of avascular necrosis of bone than the cumulative dose.[30] No case of avascular necrosis was seen either in the four extensively reviewed trials on low dose GC in RA or in the COBRA trial (hyperlinks 1 and 2, http://www.annrheumdis.com/supplemental).

Many crucial questions in this area remain unanswered—namely, questions about the relevance of the dose, route of administration, and duration of GC treatment, as well as the host factors that modulate the risk. In the meantime, it is generally accepted that in patients treated with low doses of GC, osteonecrosis is uncommon. Primary prevention is not really possible; awareness should be increased.[31]

Myopathy

Remarkably, a search of the literature showed an absence of data on, and proper studies of, myopathy. A recent review on this subject supports this contention.[32] Based on the scarce information available and our own experience, we believe that myopathy is exceedingly rare with GC doses of <7.5 mg prednisolone equivalent daily. Chronic steroid myopathy is quite often suspected, but not often found or documented. The clinical picture can be difficult to distinguish from the effects of the underlying disease, especially in the case of musculoskeletal conditions, such as myositis or inflammatory arthritis.[33] On electromyographic examination no spontaneous electrical activity is found; the serum aldolase and creatine kinase level are normal, but creatinuria may be increased. These findings are considered suggestive of steroid myopathy.[34] Diagnosis can be ascertained by muscle biopsy, showing atrophy of type II fibres, and absence of inflammation. There are no real preventative or individual risk factors to be evaluated; awareness will facilitate early recognition of this problem. No cases of myopathy were seen in the four extensively reviewed trials on low dose GC in RA (hyperlink 1, http://www.annrheumdis.com/supplemental).

ENDOCRINE AND METABOLIC ADVERSE EFFECTS

Glucose intolerance and diabetes

GC increase serum glucose levels through an increase in hepatic glucose production and changes in insulin production and resistance.[35–40] In patients without pre-existing abnormalities of glucose tolerance, GC cause slightly increased fasting glucose levels and a more pronounced increase of postprandial values. The increment follows a similar pattern in diabetic patients but tends to be more pronounced in longstanding diabetes.[41 42]

GC related hyperglycaemia is dose dependent. However, low dose GC also have this effect. One case-control study suggested an increased risk (odds ratio = 1.8) for initiation of anti-hyperglycaemic drugs during GC treatment using 0.25–2.5 prednisone equivalent a day.[43] Hyperglycaemia can also be observed after intra-articular GC.[44] It is likely that subjects with risk factors for the development of diabetes mellitus, such as a family history of this disease, increasing age, obesity, and previous gestational diabetes mellitus, are at increased risk of developing new onset hyperglycaemia during GC treatment.[41] This is usually rapidly reversed when GC are stopped, but some patients will go on to develop persistent diabetes.[45]

Next to the average daily dose, the type of GC is of great importance. Dexamethasone is 30 times and prednisone four times as potent as hydrocortisone in the impairment of glucose metabolism.[46] The suggestion that deflazacort may be less prone to cause hyperglycaemia than prednisone must be questioned based on the probably inadequate correction for glucocorticoid potency.[47]

Data from the four extensively reviewed trials on low dose GC in RA are quite reassuring in this respect: no cases of new onset diabetes were seen in either of the studies. The Utrecht trial found the least favourable results[4]: a significant increase in mean (SD) fasting glucose was seen in the prednisone group (from 5.1 (0.6) at baseline to 5.9 (1.9) mmol/l at 2 years, $p = 0.01$). However, even in this study, hyperglycaemia, as defined by the World Health Organisation, developed in only two patients in the prednisone group ($n = 40$) and one in the placebo group ($n = 41$) (hyperlink 1, http://www.annrheumdis.com/supplemental).

There are no preventive measures apart from the use of lower doses of GC. Alternate day treatment is associated with alternate day hyperglycaemia.[48]

In patients with insulin dependent diabetes exposed to very high doses of GC after kidney transplantation, an insulin dose 58% higher than in those not receiving GC was necessary.[49 50] We could find no studies on the specific effects of low dose GC in diabetic patients. A relevant and detailed discussion of glucose control under GC treatment has been published.[42]

Fat redistribution and body weight

One of the most notable effects of chronic endogenous and exogenous GC excess is the redistribution of body fat. Centripetal fat accumulation with sparing of the extremities is a characteristic feature of patients exposed to long term high dose GC. It is seen even with low dose GC. Potential mechanisms include hyperinsulinaemia, changes in expression and activity of adipocyte derived hormones and cytokines, such as leptin and tumour necrosis factor α, increased food intake (GC increase appetite), and muscle atrophy.[51–55]

Our own review of toxicity data from the four RA prospective trials shows that low dose prednisone is associated with an increase of mean body weight over 2 years, in the range of 4–8%. In two of these trials, this weight gain was significantly higher than in the placebo group[3 4] These observations were confirmed in the COBRA trial, but the differences were nullified after prednisone was stopped. However, patients in the control groups also gained weight (hyperlinks 1 and 2, http://www.annrheumdis.com/supplemental).

Suppression of sex hormone secretion

GC in high doses decrease gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, decrease basal and GnRH-stimulated luteinising hormone secretion from the pituitary, and decrease the responsiveness of gonadal cells to luteinising hormone, leading to lower levels of oestrogens[56] and testosterone.[57 58] This latter effect predominates in men.[59] These suppressing effects can contribute to steroid-induced osteoporosis. Despite these observations, it has been suggested that glucocorticoid treatment in rheumatic diseases does not cause a clinically relevant adverse effect on fertility,[60] and decreased libido has not been reported as a common complaint in patients exposed to low dose GC. In the four extensively reviewed trials on low dose GC in RA, decreased libido was not reported spontaneously.

CARDIOVASCULAR ADVERSE EFFECTS

Dyslipidaemia, atherosclerosis, and cardiovascular disease

GC treatment is considered to be a risk factor for dyslipidaemia and atherosclerosis.[61–64] Several studies in patients with SLE suggest that GC treatment is dose dependently associated with hypercholesterolaemia: significant changes were seen only at prednisone doses higher than 10 mg/day.[65–67] Beyond induction of dyslipidaemia, the role of GC in atherosclerosis is controversial. Longer steroid use is significantly associated with coronary artery disease in patients with SLE.[68–70] Also a study in patients with RA suggested that

GC treatment early in the disease course increased the risk of coronary artery disease.[71] On the other hand, in a study using an animal model of atherosclerosis,[72] although administration of dexamethasone induced hyperlipidaemia, it also reduced aortic plaque formation, an effect attributed to inhibition of infiltration of inflammatory and foam cells in the plaques. The recognition of an association between raised C reactive protein and accelerated coronary artery disease offers a theoretical basis for GC benefit on atherosclerotic disease in inflammatory diseases.[73] Furthermore, recent data from cohorts show that RA disease activity unfavourably alters the blood lipid profile, and that treatment (including GC treatment) can reverse these changes.[74] In the four extensively reviewed trials on low dose GC treatment in RA, lipids were not routinely assessed.

> ''Evidence is lacking to show that low dose GC, unlike high dose GC, significantly increase the incidence of cardiovascular disease in RA''

Recently, a record linkage database study on 68 781 GC users (of whom 1115 patients had RA) and 82 202 non-users was published.[75] The incidence of all cardiovascular diseases, including myocardial infarction, heart failure, and cerebrovascular disease, was not increased in patients using <7.5 mg/day prednisolone long term. However, it was increased in patients using doses ⩾7.5 mg daily: relative risk adjusted for all known risk factors 2.6, 95% confidence interval 2.2 to 3. In the four extensively reviewed trials on low dose GC treatment in RA and in the COBRA trial, no excess cardiovascular events were reported, but the trial duration of 2 years was relatively short for development of these complications.

In summary, the evidence does not support a significant role for low dose GC treatment on the development of cardiovascular disease in RA, in contrast with higher doses. In patients with RA receiving low dose GC, the disease itself seems to be a greater risk factor.

Water and electrolyte balance, oedema, renal and heart function

Hypernatraemia, hypokalaemia, and sodium and water retention are mineralocorticoid effects, produced by endogenous GC at supraphysiological concentrations.[76] These effects may lead to oedema and contribute to hypertension and heart failure in patients with Cushing's disease. However, synthetic GC (prednisone, prednisolone, methylprednisolone, dexamethasone) have little mineralocorticoid effects, and their administration increases the glomerular filtration rate and induces kaliuresis and natriuresis without any change in plasma volume.[77–86] A small number of trials have evaluated chronic GC administration in moderate to high doses in patients with heart failure, and no significant detrimental effect on heart function emerged from these studies.[87 88] In the four extensively reviewed trials on low dose GC treatment in RA as well as in the COBRA trial, no cardiac insufficiency attributable to GC occurred.

Hypertension

Induction of hypertension is a well demonstrated adverse effect of GC, seen in about 20% of patients exposed to exogenous GC.[89] The mechanisms involved have not been fully elucidated.[90] A retrospective study of 195 patients with RA or asthma undergoing GC treatment with <20 mg/day prednisone for longer than a year,[91] did not show any correlation between dose or duration of GC treatment and rise in blood pressure.

Toxicity data from the four extensively reviewed trials on low dose GC in RA are very reassuring about the effect on blood pressure: prednisone had no significant effects on blood pressure in any of the trials. During the first phase of the COBRA trial, the mean blood pressure was at some time points higher in the prednisone than in the placebo group, but high to medium doses of GC were used. Note that patients with severe hypertension were excluded from most of these trials (hyperlinks 1 and 2, http://www.annrheumdis.com/supplemental).

These results suggest that glucocorticoid-induced hypertension is dose related and is less likely with medium or low dose treatment. Individual variation in susceptibility and other factors, such as the basal level of blood pressure, diet salt, functional renal mass, associated diseases, and drug treatment, may have a role in the development of glucocorticoid-induced hypertension.[89] Some authors suggest that the use of alternate day regimens may reduce the tendency towards blood pressure increase,[92] but evidence for this is weak.

Other cardiac adverse effects

Incidences of arrhythmia[93] and sudden death are rare and mostly limited to patients receiving high dose pulse GC.[94 95] In the four extensively reviewed trials on low dose GC treatment in RA and in the COBRA trial, these events were not reported.

DERMATOLOGICAL ADVERSE EFFECTS

Clinically relevant adverse effects on the skin include iatrogenic Cushing's syndrome, catabolic effects (cutaneous atrophy, purpura, striae, easy bruisability, and impaired wound healing), steroid acne, and hair effects.[96] Cushingoid phenotype is seen in over 5% of the patients exposed to ⩾5 mg prednisone equivalent for ⩾1 year.[97–99] The incidence of iatrogenic Cushing's syndrome is dose dependent and, in general, becomes evident after at least 1 month of GC treatment.[96] Some authors suggest that alternate day administration decreases the development of cushingoid features,[100] but this has not been clearly established.

Catabolic effects on the skin may appear during local and systemic GC treatment. Cutaneous atrophy mainly results from the effect of GC on keratinocytes and fibroblasts. Decreased vascular structural integrity is probably a key determinant of purpura and easy bruisability in GC treated patients.[101] These effects were reported to affect over 5% of those exposed to ⩾5 mg prednisone equivalent a day for ⩾1 year.[97 102 103] Wound healing impairment seems uncommon at low dose, but there are no exact data on prevalence. There are no data on the incidence of steroid acne and hair effects like hirsutism and hair loss, but they are more common with long term treatment with medium to high doses of GC, such as those used after organ transplantation.[96] These effects of GC may sometimes be difficult to separate from those of the disease itself (for example, hair loss in SLE) and other medications.

Most of the cutaneous adverse effects of GC are not considered serious by the doctor, but they may represent a considerable cosmetic problem for the patient. Available data suggest that these effects are relatively uncommon and of minor clinical concern with low dose GC treatment, although data on incidence are scarce. There is no strong evidence to support the claim that use of the lowest possible dose and alternate day treatment may fully prevent these adverse effects. In the four extensively reviewed trials on low dose GC treatment in RA and in the COBRA study, serious cutaneous adverse effects were not reported, but the trial duration was relatively short for development of these complications.

OPHTHALMOLOGICAL ADVERSE EFFECTS

Cataract

Long term use of systemic GC may induce formation of posterior subcapsular cataract, characterised by disruption of the ordered maturation of the lens fibres, which then

accumulate on the front surface of the posterior lens capsule. Cortical cataracts have also been attributed to GC.[104]

Reports on the incidence of cataract with long term low dose systemic GC treatment are scarce. In a group of patients with RA treated with 5–15 mg/day prednisone (mean (SD) 6 (3) mg/day) for a mean (SD) of 6 (5) years, 15% were found to have cataracts, compared with 4.5% of matched RA controls not using prednisone.[14] There is no evidence that alternate day treatment reduces the risk.[105] Cataract formation is considered to be irreversible. We could find no evidence of the possibility of halting progression by reducing the dose or interrupting treatment. More careful prospective assessment of cataract formation among GC users is needed to answer this question definitively. In the four extensively reviewed trials on low dose GC treatment in RA and in the COBRA study, excess cataracts were not reported, but the trial duration was probably too short for development of this complication and only two of the four extensively reviewed trials on low dose GC treatment in RA included a regular ophthalmological check in a significant number of patients.

Glaucoma

Systemic GC increase the risk of glaucoma and may result in visual field loss or even blindness. In the general population, 18–36% of those exposed to GC had an increase in intraocular pressure.[106] Open angle glaucoma was found in 6/32 (19%) rheumatic patients exposed to $\geqslant$7.5 mg/day prednisone equivalent for more than 1 year and in 1/38 (3%) patients treated with $<$7.5 mg/day prednisone equivalent (Tryc A, Bartholome B, Buttgereit F, *et al*, unpublished data).

However, the occurrence and magnitude of the increase in intraocular pressure with GC administration are highly variable between patients.[107] A high incidence of this adverse effect with GC use tends to occur in families, suggesting a genetic basis.[108] Patients with pre-existing glaucoma are especially sensitive: 46–92% of patients with open angle and 65% of those with closed angle glaucoma will have this condition aggravated upon exposure to GC.[106 109] Patients with diabetes mellitus, high myopia, and relatives of those with open angle glaucoma are reported to be more vulnerable to GC-induced glaucoma.[106] A rise in intraocular pressure with exogenous GC is generally reversible when treatment is stopped, although it may take several weeks. Medications that lower intraocular pressure may control even a significant pressure increase induced by concomitant GC.[110] As glaucoma often is asymptomatic and can lead to severe loss of sight, regular eye pressure checks are recommended for patients receiving high dose long term systemic GC treatment, especially for those with associated risk factors for glaucoma. For patients receiving low dose GC treatment and who have no additional risk factors for glaucoma, it is generally stated that routine checks seem not to be indicated. Only two of the four extensively reviewed trials on low dose GC treatment in RA included a regular ophthalmological check in a significant number of patients. However, these checks suggest an increased risk of glaucoma with prednisone (hyperlink 1, http://www.annrheumdis.com/supplemental).

GASTROINTESTINAL ADVERSE EFFECTS

Peptic ulcer disease

The association between GC use and the risk of peptic ulcer disease has been the subject of extensive debate and contradictory evidence.[111–113] The influence of the underlying disease on the risk of peptic ulceration is difficult to isolate. Piper *et al* performed a nested control study including 1415 patients admitted to the hospital for gastroduodenal ulcer or haemorrhage and 7063 randomly selected controls from Medicaid.[114] The overall estimated relative risk for peptic ulcer disease among current GC users was 2.0 (95% CI 1.3 to 3.0). However, this increased risk was almost completely due to co-treatment with non-steroidal anti-inflammatory drugs (NSAIDs): the relative risk for patients co-medicated with NSAIDs was 4.4 (95% CI 2.0 to 9.7), but for those receiving only GC there was no significant increase in risk: 1.1 (95% CI 0.5 to 2.1). In large scale studies based on the UK General Practice Research Database,[115] the relative risk of upper gastrointestinal (GI) complications was 1.8 (95% CI 1.3 to 2.4) for users of GC compared with non users. The risk tended to be greater for higher GC doses, but this trend was not statistically significant. The risk was shown to be more than 12 times higher for concomitant users of both GC and NSAIDs than for non-users of either drug. Data from the four RA prospective trials and the COBRA study show no increased incidence of upper GI ulcers and bleeds, but these events are relatively uncommon and may not be detected in these clinical trials with a relatively low number of participating patients (hyperlink 1, http://www.annrheumdis.com/supplemental). In patients treated with GC without concomitant use of NSAIDs there thus seems to be no indication for gastroprotective agents if there are no (other) risk factors for peptic complications.

Pancreatitis

Although GC are usually listed as one of the many potential causes of pancreatitis, evidence for such an association is weak and difficult to separate from the influence of the underlying disease, such as SLE or vasculitis. Experimental and postmortem studies suggest that GC use is associated with an increased incidence of pancreatitis. In one post-mortem study, acute pancreatitis or fat necrosis was seen in 29% of those treated with adrenocorticotropic hormone or GC compared with 4% in the controls.[116] However, none of these patients had been diagnosed with pancreatitis *premortem*, suggesting that clinically relevant pancreatitis due to GC is rare. Controlled studies showed that GC treatment does not cause an increased incidence of pancreatitis in patients with SLE.[117] In the four extensively reviewed trials on low dose GC treatment in RA and in the COBRA study, no case of pancreatitis was reported.

INFECTIOUS ADVERSE EFFECTS

The use of GC is associated with increased susceptibility to various viral, bacterial, fungal, and parasitic infections. The mechanisms underlying this effect are manifold and not completely understood.[118] Most of these mechanisms, such as the decrease in function of monocytes, subside rapidly when treatment is interrupted, an observation that may explain the lower infectious risk with the use of short acting GC and alternate day treatment.[119 120] The risk of infection increases with dose and duration of treatment,[121] and tends to remain low in patients exposed to low doses, even with high cumulative dosages.[122] In a meta-analysis of 71 trials involving over 2000 patients with different diseases and different dosages of GC, a relative risk of infection was found of 2.0.[123] Five of these 71 trials involved patients with rheumatic diseases and showed no increased relative risk. In two studies specifically on RA the incidence of serious infections was found to be similar to that of placebo or only slightly increased.[4 14] SLE is associated with an increased risk of opportunistic infections, exacerbated by treatment with GC.[124 125] Of the intensively reviewed four studies of low dose GC treatment in RA, both in the Utrecht and the WOSERACT trials, prednisone up to 10 mg/day was not associated with increased incidence of any kind of infections over the 2 years of the trials.[4 5]

In patients treated with GC, physicians should anticipate the risk of infections with both usual and unusual organisms, realising that GC may blunt the classic clinical features and

delay the diagnosis. Under special clinical circumstances and in severely immunocompromised patients it may be wise to screen for latent infections, such as tuberculosis, or institute prophylactic chemotherapy.[122] *Pneumocystis carinii* infections deserve special attention, as doses as low as 16 mg/day prednisone for 8 weeks have been associated with increased risk in one series.[126]

PSYCHOLOGICAL AND BEHAVIOURAL DISTURBANCES

Steroid psychosis

Psychosis is characterised by hallucinations, delusions, or both. Reported estimates of the incidence of steroid psychosis vary greatly (0–60%), owing to differences in study groups and methodology of assessing this adverse event. Following an authoritative review, the estimate of incidence of 5–6% has become consensual in the literature.[127] However, most cases are associated with high doses of GC and an influence of the underlying disease, such as SLE, is often difficult to exclude. A landmark study in this area is the Boston Cooperative Drug Surveillance Program.[128] The incidence of steroid psychosis in 718 prednisone treated patients was 1.3% at 40 mg daily, 4–5% at 41–80 mg/day, and >18% with higher doses. Several studies examining doses of ⩽20 mg did not find cases of psychosis.[129] This adverse event was not reported either in the four extensively reviewed trials on low dose GC treatment in RA, or in the COBRA study.

> ''Psychosis induced by glucocorticoids is rare with low dose regimens''

Thus the clinician should be aware of this adverse effect and its clinical features,[130 131] but overt psychosis is extremely rare with the low and medium dose regimens usually employed in rheumatology.

Minor mood disturbances

GC treatment has been associated with a variety of low grade disturbances such as depressed or elated mood (euphoria), irritability or emotional lability, anxiety and insomnia, memory and cognition impairments. The exact incidence of such symptoms in rheumatic patients exposed to common doses of GC cannot be drawn from the literature. Most studies relate to doses of 80–160 mg of prednisone equivalent a day, far exceeding common long term regimens in rheumatology.[132] Evidence for minor effects is scarce, but doses of <20–25 mg prednisone equivalent a day are associated with few or no significant disturbances.[133 134] However, individual susceptibility is highly variable and in a few published cases a relationship between low dose GC and even topical steroids and psychotic episodes seems hard to doubt. These adverse events were not reported or systematically assessed in the four extensively reviewed trials on low dose GC treatment in RA, or in the COBRA study.

DRUG INTERACTIONS

Significant interactions between GC and other prescription treatments have been well documented. Drugs that *reduce* the systemic GC concentration may diminish clinical efficacy. They include large doses of aluminium/magnesium hydroxide, which decrease prednisone bioavailability by 30–40%,[135 136] and most anticonvulsant drugs (for example, phenobarbital, phenytoin), which enhance the metabolism of GC.[137–142] Rifampicin accelerates the metabolism of synthetic GC, as may St John's wort.[143] Non-responsiveness of inflammatory diseases to prednisone, induced by rifampicin, has been described and rifampicin-induced adrenal crisis in patients receiving GC replacement treatment has been documented.[144–147]

Drugs that *raise* the systemic GC concentration include some oral contraceptives,[148–151] antibiotics (erythromycin and troleandomycin).[152–154] Antifungal agents, particularly ketoconazole decrease GC metabolising enzymes.[155 156] Some data suggest that several NSAIDs, including indometacin and naproxen, increase GC concentrations.[157] Conversely, GC may affect serum concentration, efficacy, or toxicity of other drugs, such as warfarin and salicylates.[158 159] In addition, when used concomitantly with traditional NSAIDs, GC cause an increased risk of upper GI adverse events, particularly in patients with RA (see above).[115 160]

Neither the four extensively reviewed trials on low dose GC treatment in RA, nor the COBRA study, were adequate to study these interactions.

CONCLUSIONS AND RESEARCH AGENDA

After a careful literature review of the adverse effects of low dose GC, an extensive review of the adverse effects of four trials on low dose GC treatment in RA and the COBRA study, and extensive group discussions, our main conclusion is that definitive associations of low dose GC with many adverse effects remain elusive. The overall fear of GC toxicity in RA, as quoted in textbooks and review articles, is probably overestimated, based on extrapolation from observations with higher dose treatment. The balance of risks and benefits of low dose treatment clearly differs from that of medium and high dose treatment, for which the mechanisms of action of GC may be different.[161] This may explain why GC are used in practice in more patients than the more pessimist recommendations suggest. Physicians, and probably patients, seem to value the benefit/risk ratio of low dose GC. The evidence on which to support clear recommendations about toxicity of low dose GC is surprisingly weak. The literature and the recent trial results suggest that routine toxicity monitoring for patients receiving low dose GC is not currently justifiable or cost effective based on existing evidence. However, patients with additional risk factors (for example, osteoporosis, obesity, hypertension, a family history of diabetes or glaucoma) merit more careful observation (table 2).

GC will probably be used with enormous therapeutic value in the treatment of a large variety of rheumatic conditions for many years to come, especially because it becomes increasingly clear that they have disease modifying potential. The data reported in this paper of trials not primarily designed for assessment of adverse effects and of observational studies with possible bias, especially confounding by indication, do not represent the highest level of evidence. So the safety of low dose GC also needs to undergo serious and systematic re-evaluation with properly designed and dedicated studies of adequate size, duration, and using state of the art end points. Guidelines for such studies would enhance comprehensiveness and comparability. We believe the areas listed in table 2 should be further explored when new studies of low dose GC are undertaken, and physicians might wish to consider these issues in clinical practice when prescribing GC treatment.

Table 2 Glucocorticoid related adverse effects other than osteoporosis that may justify regular checks

- Cushingoid symptoms
- Adrenal crisis on glucocorticoid withdrawal
- Growth retardation in children
- New onset of diabetes mellitus in subjects at risk for developing DM
- Worsening of glycaemia control in patients with diabetes mellitus
- Cataracts and glaucoma
- Peptic ulcer (in combination with NSAIDs)
- Hypertension

Furthermore, subjects participating in randomised clinical trials may not have the same disease characteristics or comorbidities as patients treated in the community, thereby limiting the generalisability of findings of this kind of trial.[162] So, simple, pragmatic trials with appropriate patient selection and sufficiently long duration are also needed.

Other areas of research include the best timing of administration, the potential advantages and limitations of alternate day dosing, identification of risk factors for such adverse effects as upper GI complications, glaucoma, cataract, and studies of the individual sensitivity to GC related to underlying mechanisms, such as receptor gene polymorphisms.[163] Elucidation of the biological mechanisms involved in these effects will open new opportunities for prevention and treatment. Research on the potential separation of wanted from unwanted GC effects using newly designed GC-type medicine provides good reason to hope that an even better safety/efficacy ratio can be achieved in the future.[164]

Authors' affiliations

J A P Da Silva, L B S Inês, Reumatologia, Hospitais da Universidade de Coimbra, Portugal
J W G Jacobs, J W J Bijlsma, Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands
J R Kirwan, University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK
M Boers, Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands
K G Saag, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, USA
E J P de Koning, Leiden University Medical Centre, Departments of Nephrology and Endocrinology, Leiden, The Netherlands
F Buttgereit, Charité Universitätsmedizin Berlin, Germany
M Cutolo, Research Laboratory and Division of Rheumatology, Department of Internal Medicine, University of Genova, Italy
H Capell, Centre for Rheumatic Diseases, Royal Infirmary Glasgow, Scotland, UK
R Rau, Department of Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany

Competing interest: None.

REFERENCES

1 **Kirwan JR**. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. *N Engl J Med* 1995;**333**:142–6.
2 **Hickling P**, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. *Br J Rheumatol* 1998;**37**:930–6.
3 **Wassenberg S**, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005;**52**:3371–80.
4 **van Everdingen AA**, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. *Ann Intern Med* 2002;**136**:1–12.
5 **Capell HA**, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, *et al*. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. *Ann Rheum Dis* 2004;**63**:797–803.
6 **Laan RF**, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. *Ann Intern Med* 1993;**119**:963–8.
7 **de Nijs RN**, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH, *et al*. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2001;**40**:1375–83.
8 **van Staa TP**, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int* 2002;**13**:777–87.
9 **Gluck OS**, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. *Arthritis Rheum* 1981;**24**:892–8.
10 **Ruegsegger P**, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. *Eur J Clin Pharmacol* 1983;**25**:615–20.
11 **Verhoeven AC**, Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. *J Rheumatol* 1997;**24**:1495–503.
12 **Lodder MC**, Lems WF, Kostense PJ, Verhoeven AC, Dijkmans BA, Boers M. Bone loss due to glucocorticoids: update of a systematic review op prospective studies in rheumatoid arthritis and other diseases [abstract]. *Ann Rheum Dis* 2003;**62**(suppl 1):94.
13 **Bijlsma JWJ**. Long-term glucocorticoid treatment of rheumatoid arthritis: risk or benefit? *Rheumatology in Europe* 1998;**27**:67–71.
14 **Saag KG**, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, *et al*. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med* 1994;**96**:115–23.
15 **van Staa TP**, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. *J Bone Miner Res* 2000;**15**:993–1000.
16 **Reid IR**, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. *Arch Intern Med* 1990;**150**:2545–8.
17 **Lems WF**, Jahangier ZN, Jacobs JW, Bijlsma JW. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. *Clin Exp Rheumatol* 1995;**13**:293–7.
18 **Naganathan V**, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. *Arch Intern Med* 2000;**160**:2917–22.
19 **Sambrook P**, Lane NE. Corticosteroid osteoporosis. *Best Pract Res Clin Rheumatol* 2001;**15**:401–13.
20 **Boers M**, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, *et al*. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;**350**:309–18.
21 **Dequeker J**, Westhovens R, Luyten FP. Rheumatic disorders and glucocorticoid-induced osteoporosis. *Front Horm Res* 2002;**30**:107–20.
22 **Yeap SS**, Hosking DJ. Management of corticosteroid-induced osteoporosis. *Rheumatology (Oxford)* 2002;**41**:1088–94.
23 **Anonymous**. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. *Arthritis Rheum* 2001;**44**:1496–503.
24 **Eastell R**, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, *et al*. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. *J Intern Med* 1998;**244**:271–92.
25 **Anonymous**. Guidelines on the prevention and treatment of glucocorticoid induced osteoporosis by the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. http://www.rcplondon.ac.uk/pubs/books/glucocorticoid (accessed 21 November 2004).
26 **Ninomija S**. An epidemiologic survey of idiopathic avascular necrosis of the femoral head in Japan. *Annual Report of Japanese Investigation Committee for Intractable Disease*. Osaka: University Publisher, 1984.
27 **Zizic TM**, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. *Am J Med* 1985;**79**:596–604.
28 **Gebhard KL**, Maibach HI. Relationship between systemic corticosteroids and osteonecrosis. *Am J Clin Dermatol* 2001;**2**:377–88.
29 **Vreden SG**, Hermus AR, van Liessum PA, Pieters GF, Smals AG, Kloppenborg PW. Aseptic bone necrosis in patients on glucocorticoid replacement therapy. *Neth J Med* 1991;**39**:153–7.
30 **Zonana-Nacach A**, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum* 2000;**43**:1801–8.
31 **Klipple JH**. *Osteonecrosis. Primer on the rheumatic diseases*. Atlanta, USA: Arthritis Foundation, 2001:503–6.
32 **Kagen LJ**. Steroid myopathy. In: Lin NA, Paget SA, eds. *Principles of corticosteroid therapy*. London: Arnold, 2002:87–90.
33 **Danneskiold-Samsoe B**, Grimby G. The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis. *Clin Sci (Lond)* 1986;**71**:693–701.
34 **Moxley RT**. Metabolic and endocrine myopathies. In: Walton JN, Karpati G, Jones DH, eds. *Disorders of voluntary muscle*. Edinburgh: Churchil Livingstone, 1994:647.
35 **Tayek JA**, Katz J. Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relationship to serum cortisol. *Am J Physiol* 1997;**272**:E476–84.
36 **Delaunay F**, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, *et al*. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. *J Clin Invest* 1997;**100**:2094–8.
37 **Lambillotte C**, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. *J Clin Invest* 1997;**99**:414–23.
38 **Hosker JP**, Burnett MA, Matthews DR, Turner RC. Prednisolone enhances beta-cell function independently of ambient glycemic levels in type II diabetes. *Metabolism* 1993;**42**:1116–20.
39 **Kautzky-Willer A**, Thomaseth K, Clodi M, Ludvik B, Waldhausl W, Prager R, *et al*. Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. *Metabolism* 1996;**45**:486–91.
40 **Tounian P**, Schneiter P, Henry S, Delarue J, Tappy L. Effects of dexamethasone on hepatic glucose production and fructose metabolism in healthy humans. *Am J Physiol* 1997;**273**:E315–20.

41 **Hirsch IB**, Paauw DS. Diabetes management in special situations. *Endocrinol Metab Clin North Am* 1997;**26**:631–45.
42 **Hoogwerf B**, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. *Rheum Dis Clin North Am* 1999;**25**:489–505.
43 **Gurwitz JH**, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. *Arch Intern Med* 1994;**154**:97–101.
44 **Black DM**, Filak AT. Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection. *J Fam Pract* 1989;**28**:462–3.
45 **Hricik DE**, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. *Transplantation* 1991;**51**:374–7.
46 **Liapi C**, Chrousos GP. Glucocorticoids. In: Yaffe SJ, Arand JV, eds. *Pediatric pharmacology*. Philadelphia: Saunders, 1992:466.
47 **Bruno A**, Cavallo-Perin P, Cassader M, Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. *Arch Intern Med* 1987;**147**:679–80.
48 **Greenstone MA**, Shaw AB. Alternate day corticosteroid causes alternate day hyperglycaemia. *Postgrad Med J* 1987;**63**:761–4.
49 **Barbosa J**, Menth L, Eaton J, Sutherland D, Freier EF, Najarian J. Long-term, ambulatory, subcutaneous insulin infusion versus multiple daily injections in brittle diabetic patients. *Diabetes Care* 1981;**4**:269–74.
50 **Ekstrand A**, Ahonen J, Gronhagen-Riska C, Groop L. Mechanisms of insulin resistance after kidney transplantation. *Transplantation* 1989;**48**:563–8.
51 **Licinio J**, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, *et al*. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. *Nat Med* 1997;**3**:575–9.
52 **Stewart PM**, Tomlinson JW. Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity. *Trends Endocrinol Metab* 2002;**13**:94–6.
53 **Tomlinson JW**, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, *et al*. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. *Endocrinology* 2001;**142**:1982–9.
54 **Reilly JJ**, Brougham M, Montgomery C, Richardson F, Kelly A, Gibson BE. Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. *J Clin Endocrinol Metab* 2001;**86**:3742–5.
55 **Tataranni PA**, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. *Am J Physiol* 1996;**271**:E317–25.
56 **Nordin BE**, Crilly RG, Marshall DH, Barkworth SA. Oestrogens, the menopause and the adrenopause. *J Endocrinol* 1981;**89**(suppl):131–43P.
57 **Hampson G**, Bhargava N, Cheung J, Vaja S, Seed PT, Fogelman I. Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. *Metabolism* 2002;**51**:1458–62.
58 **MacAdams MR**, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. *Ann Intern Med* 1986;**104**:648–51.
59 **Cumming DC**, Quigley ME, Yen SS. Acute suppression of circulating testosterone levels by cortisol in men. *J Clin Endocrinol Metab* 1983;**57**:671–3.
60 **Janssen NM**, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. *Arch Intern Med* 2000;**160**:610–19.
61 **Becker DM**, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, *et al*. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. *Am J Med* 1988;**85**:632–8.
62 **Cattran DC**, Steiner G, Wilson DR, Fenton SA. Hyperlipidemia after renal transplantation: natural history and pathophysiology. *Ann Intern Med* 1979;**91**:554–9.
63 **Curtis JJ**, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. *Kidney Int* 1982;**22**:42–7.
64 **el-Shaboury AH**, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. *BMJ* 1973;**2**:85–6.
65 **MacGregor AJ**, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, *et al*. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. *Ann Rheum Dis* 1992;**51**:152–5.
66 **Petri M**, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. *Medicine (Baltimore)* 1992;**71**:291–302.
67 **Leong KH**, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. *J Rheumatol* 1994;**21**:1264–7.
68 **Manzi S**, Meilahn EN, Rairie JE, Conte CG, Medsger TA J. Jansen-McWilliams L, *et al*. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study, *Am J Epidemiol* 1997;**145**:408–15.
69 **Petri M**, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. *Am J Med* 1992;**93**:513–19.
70 **Manzi S**, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, *et al*. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. *Arthritis Rheum* 1999;**42**:51–60.
71 **Wallberg-Jonsson S**, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. *J Rheumatol* 1999;**26**:2562–71.
72 **Asai K**, Funaki C, Hayashi T, Yamada K, Naito M, Kuzuya M, *et al*. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. *Arterioscler Thromb* 1993;**13**:892–9.
73 **Munford RS**. Statins and the acute-phase response. *N Engl J Med* 2001;**344**:2016–18.
74 **Boers M**, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE, *et al*. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. *Ann Rheum Dis* 2003;**62**:842–5.
75 **Wei L**, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med* 2004;**141**:764–70.
76 **Connell JM**, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. *J Hypertens* 1987;**5**:425–33.
77 **Bia JM**, Tyler K, DeFronzo RA. The effect of dexamethasone on renal electrolyte excretion in the adrenalectomized rat. *Endocrinology* 1982;**111**:882–8.
78 **Campen TJ**, Vaughn DA, Fanestil DD. Mineralo- and glucocorticoid effects on renal excretion of electrolytes. *Pflugers Arch* 1983;**399**:93–101.
79 **Hall JE**, Morse CL, Smith MJ Jr, Young DB, Guyton AC. Control of arterial pressure and renal function during glucocorticoid excess in dogs. *Hypertension* 1980;**2**:139–48.
80 **Kohlmann O**, Ribeiro AB, Marson O, Saragoca MA, Ramos OL. Methylprednisolone-induced hypertension. Role for the autonomic and renin angiotensin systems. *Hypertension* 1981;**3**:II-11.
81 **Krakoff LR**, Selvadurai R, Sutter E. Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. *Am J Physiol* 1975;**228**:613–17.
82 **Kurokawa K**, Fukagawa M, Hayashi M, Saruta T. Renal receptors and cellular mechanisms of hormone action in the kidney. In: Seldin DW, Giebisch G, eds. *The kidney: physiology and pathophysiology*. New York: Raven Press, 1992:1339–72.
83 **Nakamoto H**, Suzuki H, Kageyama Y, Ohishi A, Murakami M, Naitoh M, *et al*. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. *Clin Exp Hypertens A* 1991;**13**:587–606.
84 **Nelson MA**, Coghlan JP, Denton DA, Mills EH, Spence CD, Scoggins BA. Metabolic and blood pressure effects of 6 alpha-methylprednisolone in the conscious sheep. *Clin Exp Hypertens A* 1984;**6**:1067–75.
85 **Okuno T**, Suzuki H, Saruta T. Dexamethasone hypertension in rats. *Clin Exp Hypertens* 1981;**3**:1075–86.
86 **Whitworth JA**, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. *J Hypertens* 1989;**7**:537–49.
87 **Latham RD**, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. *Am Heart J* 1989;**117**:876–82.
88 **Mason JW**, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, *et al*. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. *N Engl J Med* 1995;**333**:269–75.
89 **Whitworth JA**. Mechanisms of glucocorticoid-induced hypertension. *Kidney Int* 1987;**31**:1213–24.
90 **Sholter DE**, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. *Can J Cardiol* 2000;**16**:505–11.
91 **Jackson SH**, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? *Clin Sci (Lond)* 1981;**61**(suppl 7):381–3s.
92 **McHugh MI**, Tanboga H, Wilkinson R. Alternate day steroids and blood pressure control after renal transplantation. *Proc Eur Dial Transplant Assoc* 1980;**17**:496–501.
93 **Singh RG**, Kassir M, Roistacher N, Lerman BB, Kligfield P. Acceleration of atrioventricular conduction during corticosteroid therapy. *Am Heart J* 1993;**125**:1432–4.
94 **Smith RS**, Warren DJ. Effects of high-dose intravenous methylprednisolone on circulation in humans. *Transplantation* 1983;**35**:349–51.
95 **Thompson JF**, Chalmers DH, Wood RF, Kirkham SR, Morris PJ. Sudden death following high-dose intravenous methylprednisolone. *Transplantation* 1983;**36**:594–6.
96 **Wolverton SE**. Corticosteroids and the integument. In: Lin AN, Paget SA, eds. *Principles of corticosteroid therapy*. London: Arnold, 2002:166–72.
97 **Covar RA**, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. *J Allergy Clin Immunol* 2000;**106**:651–9.
98 **Marcocci C**, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, *et al*. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. *J Clin Endocrinol Metab* 2001;**86**:3562–7.
99 **Tornatore KM**, Biocevich DM, Reed K, Tousley K, Singh JP, Venuto RC. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. *Transplantation* 1995;**59**:729–36.
100 **Pedrosa MC**, Rohrer RM, Kaplan MM. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. *Clin Transplant* 1995;**9**:322–5.
101 **Davis GF**. Adverse effects of corticosteroids: II. Systemic. *Clin Dermatol* 1986;**4**:161–9.
102 **Caldwell JR**, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. *Semin Arthritis Rheum* 1991;**21**:1–11.
103 **Hatz HJ**, Helmke K. [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy]. *Z Rheumatol* 1992;**51**:213–21.

104 **Klein R**, Klein BE, Lee KE, Cruickshanks KJ, Chappell RJ. Changes in visual acuity in a population over a 10-year period: The Beaver Dam Eye Study. *Ophthalmology* 2001;**108**:1757–66.
105 **Rooklin AR**, Lampert SI, Jaeger EA, McGeady SJ, Mansmann HC Jr. Posterior subcapsular cataracts in steroid-requiring asthmatic children. *J Allergy Clin Immunol* 1979;**63**:383–6.
106 **Tripathi RC**, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. *Drugs Aging* 1999;**15**:439–50.
107 **Klemetti A**. The dexamethasone provocative test: a predictive tool for glaucoma? *Acta Ophthalmol (Copenh)* 1990;**68**:29–33.
108 **Stone EM**, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL, *et al*. Identification of a gene that causes primary open angle glaucoma. *Science* 1997;**275**:668–70.
109 **Akingbehin AO**. Corticosteroid-induced ocular hypertension. I. Prevalence in closed-angle glaucoma. *Br J Ophthalmol* 1982;**66**:536–40.
110 **Brodie S**. Corticosteroids and the eye. In: Lin AN, Paget SA, eds. *Principles of corticosteroid therapy*. London: Arnold, 2002:131–4.
111 **Conn HO**, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. *N Engl J Med* 1976;**294**:473–9.
112 **Conn HO**, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. *J Intern Med* 1994;**236**:619–32.
113 **Messer J**, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. *N Engl J Med* 1983;**309**:21–4.
114 **Piper JM**, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1991;**114**:735–40.
115 **Garcia Rodriguez LA**, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. *Arthritis Res* 2001;**3**:98–101.
116 **Carone FA**, Liebow AA. Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids. *N Engl J Med* 1957;**257**:690–7.
117 **Saab S**, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus pancreatitis: a case series. *J Rheumatol* 1998;**25**:801–6.
118 **Singh AE**, Tyrrell DL. Corticosteroids in infectious diseases. In: Lin AN, Paget SA, eds. *Principles of corticosteroid therapy*, London: Arnold, 2002:285–306.
119 **Baxter JD**. Minimizing the side effects of glucocorticoid therapy. *Adv Intern Med* 1990;**35**:173–93.
120 **Dale DC**, Fauci AS, Wolff SM. Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. *N Engl J Med* 1974;**291**:1154–8.
121 **Dale DC**, Petersdorf RG. Corticosteroids and infectious diseases. *Med Clin North Am* 1973;**57**:1277–87.
122 **Stracher AR**, Soave R. Infectious complications of corticosteroid therapy. In: Linn AN, Paget SA, eds. *Principles of corticosteroid therapy*. London: Arnold, 2002:419–30.
123 **Stuck AE**, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. *Rev Infect Dis* 1989;**11**:954–63.
124 **Godeau B**, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, *et al*. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. *J Rheumatol* 1994;**21**:246–51.
125 **Hellmann DB**, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. *Medicine (Baltimore)* 1987;**66**:341–8.
126 **Yale SH**, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin Proc* 1996;**71**:5–13.
127 **Lewis DA**, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. *J Affect Disord* 1983;**5**:319–32.
128 **Gourley MF**, Austin HA, III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. *Ann Intern Med* 1996;**125**:549–57.
129 **Smyllie HC**, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. *Thorax* 1968;**23**:571–81.
130 **Demopoulos A**, Apatoff BR. Corticosteroids and the nervous system. In: Lin NA, Paget SA, eds. *Principles of corticosteroid therapy*. London: Arnold, 2002:150–65.
131 **Patten SB**, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. *Drug Saf* 2000;**22**:111–22.
132 **Naber D**, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. *Psychoneuroendocrinology* 1996;**21**:25–31.
133 **Olsen EA**, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. *Arch Dermatol* 1992;**128**:1467–73.
134 **Reckart MD**, Eisendrath SJ. Exogenous corticosteroid effects on mood and cognition: case presentations. *Int J Psychosom* 1990;**37**:57–61.
135 **Tanner AR**, Caffin JA, Halliday JW, Powell LW. Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone. *Br J Clin Pharmacol* 1979;**7**:397–400.
136 **Uribe M**, Casian C, Rojas S, Sierra JG, Go VL. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. *Gastroenterology* 1981;**80**:661–5.
137 **Brooks SM**, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. *N Engl J Med* 1972;**286**:1125–8.
138 **Evans PJ**, Walker RF, Peters JR, Dyas J, Riad-Fahmy D, Thomas JP, *et al*. Anticonvulsant therapy and cortisol elimination. *Br J Clin Pharmacol* 1985;**20**:129–32.
139 **Frey BM**, Frey FJ. Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. *Eur J Clin Invest* 1984;**14**:1–6.
140 **Frey FJ**, Frey BM. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. *J Lab Clin Med* 1983;**101**:593–604.
141 **Petereit LB**, Meikle AW. Effectiveness of prednisolone during phenytoin therapy. *Clin Pharmacol Ther* 1977;**22**:912–16.
142 **Stjernholm MR**, Katz FH. Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. *J Clin Endocrinol Metab* 1975;**41**:887–93.
143 **Edwards OM**, Courtenay-Evans RJ, Galley JM, Hunter J, Tait AD. Changes in cortisol metabolism following rifampicin therapy. *Lancet* 1974;**2**:548–51.
144 **Carrie F**, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. *Arch Intern Med* 1994;**154**:1521–4.
145 **Kawai S**, Ichikawa Y, Homma M. [Rifampicin-induced resistance to prednisolone treatment in collagen disease–a pharmacokinetic study]. *Ryumachi* 1984;**24**:32–7.
146 **McAllister WA**, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. *BMJ (Clin Res Ed)* 1983;**286**:923–5.
147 **Kyriazopoulou V**, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. *J Clin Endocrinol Metab* 1984;**59**:1204–6.
148 **Boekenoogen SJ**, Szefler SJ, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. *J Clin Endocrinol Metab* 1983;**56**:702–9.
149 **Frey BM**, Schaad HJ, Frey FJ. Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. *Eur J Clin Pharmacol* 1984;**26**:505–11.
150 **Gustavson LE**, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. *J Clin Endocrinol Metab* 1986;**62**:234–7.
151 **Olivesi A**. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. *Biomed Pharmacother* 1986;**40**:301–8.
152 **LaForce CF**, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. *J Allergy Clin Immunol* 1983;**72**:34–9.
153 **Szefler SJ**, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. *Clin Pharmacol Ther* 1982;**32**:166–71.
154 **Szefler SJ**, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, *et al*. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. *J Allergy Clin Immunol* 1982;**69**:455–60.
155 **Yamashita SK**, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. *Clin Pharmacol Ther* 1991;**49**:558–70.
156 **Zurcher RM**, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. *Clin Pharmacol Ther* 1989;**45**:366–72.
157 **Rae SA**, Williams IA, English J, Baylis EM. Alteration of plasma prednisolone levels by indomethacin and naproxen. *Br J Clin Pharmacol* 1982;**14**:459–61.
158 **Kaufman M**. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. *Mult Scler* 1997;**3**:248–9.
159 **Klinenberg JR**, Miller F. Effect of corticosteroids on blood salicylate concentration. *JAMA* 1965;**194**:601–4.
160 **Wolfe F**, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. *J Rheumatol* 2000;**27**:1668–73.
161 **Buttgereit F**, Da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, *et al*. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. *Ann Rheum Dis* 2002;**61**:718–22.
162 **Jacobs JW**, Bijlsma JW. Interpretation of trial methodology not always easy: comment on the editorial by Landewé. *Arthritis Rheum* 2003;**48**:2693–4.
163 **Huizenga NA**, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H, *et al*. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. *J Clin Endocrinol Metab* 1998;**83**:144–51.
164 **Rhen T**, Cidlowski JA, *et al*. Antiinflammatory action of glucocorticoids—new mechanism for old drugs. *N Engl J Med* 2005;**353**:1711–23.